[Special Stock] IMBDX Reveals CancerFind Results in Europe... Early Detection Expected for 26 Cancer Types

IMBDX is showing strong performance. The news that it will present research results using its multi-cancer screening service 'CancerFind' at the European Society for Medical Oncology (ESMO) conference appears to be influencing its stock price.

Kim Tae-yu, CEO of IMBDX, said, "Early detection of cancer is a crucial factor in increasing the survival rate of cancer patients," adding, "Ultimately, we are strengthening our product competitiveness to enable early detection of more than 26 types of cancer with a single blood test, thereby securing the golden time for treating intractable cancers and contributing to public health promotion."

As of 2:01 PM on the 9th, IMBDX was trading at 18,050 KRW, up 1,230 KRW (7.31%) from the previous trading day.

Precision medicine company IMBDX announced that it will present research results using its multi-cancer screening service 'CancerFind' at the 2024 European Society for Medical Oncology (ESMO) conference, held in Spain from the 13th to the 17th of this month.

CancerFind, developed by IMBDX, is an innovative product that can detect multiple cancers (currently 8 types) early with a simple blood test, significantly reducing the economic burden of cancer treatment and improving patient survival rates.

At the 2024 ESMO, the performance of CancerFind for 8 major cancers (colorectal, stomach, liver, pancreatic, lung, breast, ovarian, and prostate cancers) will be revealed. Through an AI algorithm with greatly improved analytical performance compared to existing methods, the efficiency of analyzing cancer genomic data has been significantly enhanced. Furthermore, a foundation has been established for screening a broader range of cancer types beyond the current 8.

Notably, sensitivities of 80.6% and 84.7% were achieved for pancreatic and ovarian cancers, respectively, which currently lack standard screening tests. This is expected to present new possibilities for treating cancers that were difficult to detect early and had poor prognoses.

A company representative stated, "Given the strong market interest in early cancer screening, this presentation is a great opportunity to showcase IMBDX's potential through the excellent performance of CancerFind, and it is expected to have a positive impact not only in academia but also in global market expansion."